Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

The Centers for Medicare & Medicaid Services is planning a 33.4% cut to the reimbursement payments hospitals receive for all drugs acquired through the 340B program, according to a draft guidance published on July 7.

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS and the Centers for Medicare & Medicaid Services deferred more than $1 billion in federal Medicaid payments to California and Minnesota as these states submit additional documentation supporting certain Medicaid claims.

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

The Centers for Medicare & Medicaid Services has proposed a sweeping new Advance Care Planning quality measure (MUC2025-020) that would track end-of-life care discussions for patients 18 and older.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Podcast The Directors

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

June 26, 2026

Vol.52 No.25

By Paul Goldberg and Claire Marie Porter

Cancer Policy

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

The Centers for Medicare & Medicaid Services has released a guidance for states on how to implement Medicaid work requirements that will go into effect nationwide on Jan. 1, 2027.

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

The U.S Supreme Court has declined to hear a slew of legal challenges filed by pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis, and Boehringer Ingelheim.

May 22, 2026

Vol.52 No.20

By Sara Willa Ernst

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

YOU MAY BE INTERESTED IN

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

Renew today!

Subscriber content

Never miss an issue!

Login

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

YOU MAY BE INTERESTED IN

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas“Institutions are feeling crunched in so many different directions”

Cancer patients could be exempted from Medicaid work requirements if they prove they are “medically frail”

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

Never miss an issue!

Login

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”